Overview Dividends

(XNCR) Xencor - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98401F1057

Monoclonal Antibodies, Bispecific Antibodies, Cancer Therapies

Biotechnology
Market Cap in USD: 1,087m
IPO / Inception: 2013-12-03
Return 12m vs S&P 500: -45.9%

EPS (Earnings per Share)

EPS (Earnings per Share) of XNCR over the last years for every Quarter: "2020-12": -0.24, "2021-03": -0.04, "2021-06": 0.87, "2021-09": -0.69, "2021-12": 1.21, "2022-03": 0.39, "2022-06": -0.57, "2022-09": -0.55, "2022-12": -0.2, "2023-03": -1.02, "2023-06": -0.37, "2023-09": -0.4, "2023-12": -0.31, "2024-03": -1.11, "2024-06": -1.07, "2024-09": -0.71, "2024-12": -0.62, "2025-03": -0.66, "2025-06": -0.41, "2025-09": -0.08,
EPS CAGR: -18.84%
EPS Trend: -46.1%
Last SUE: 2.31
Qual. Beats: 2

Revenue

Revenue of XNCR over the last years for every Quarter: 2020-12: 41.854, 2021-03: 33.965, 2021-06: 67.447, 2021-09: 19.683, 2021-12: 154.015, 2022-03: 85.495, 2022-06: 30.175, 2022-09: 27.299, 2022-12: 21.61, 2023-03: 18.962, 2023-06: 45.523, 2023-09: 59.164, 2023-12: 50.966, 2024-03: 15.997, 2024-06: 16.96, 2024-09: 17.796, 2024-12: 70.018, 2025-03: 32.732, 2025-06: 43.608, 2025-09: 20.999,
Rev. CAGR: -41.22%
Rev. Trend: -34.3%
Last SUE: -0.33
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 51.3%
Value at Risk 5%th 75.2%
Relative Tail Risk -10.94%
Reward TTM
Sharpe Ratio -0.40
Alpha -58.77
CAGR/Max DD -0.20
Character TTM
Hurst Exponent 0.519
Beta 1.476
Beta Downside 1.135
Drawdowns 3y
Max DD 81.06%
Mean DD 46.72%
Median DD 45.62%

Description: XNCR Xencor December 26, 2025

Xencor, Inc. (NASDAQ: XNCR) is a clinical-stage biopharma that engineers monoclonal antibodies for asthma, allergic, autoimmune diseases and oncology. Its marketed products include Ultomiris (atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica), Monjuvi (relapsed/refractory diffuse large B-cell lymphoma) and Sotrovimab (SARS-CoV-2). The pipeline features a range of XmAb bispecific antibodies-XmAb819 (renal cell carcinoma), XmAb541 (ovarian cancer), Vudalimab (metastatic castration-resistant prostate cancer), XmAb564 (autoimmune), and several early-stage candidates targeting solid tumors, inflammatory bowel disease, HIV, hepatitis Delta, Alzheimer’s, and other indications.

As of the latest 10-K, Xencor reported FY 2023 revenue of approximately $85 million, driven primarily by royalty and collaboration payments, and held a cash runway of roughly $300 million, giving it > 12 months of liquidity at current burn. The company’s partnership with Novartis on the XmAb Fc platform and a 2022 licensing deal with J&J for a bispecific oncology program together contribute an estimated $250 million in upfront and milestone payments, underscoring the market’s appetite for engineered antibody technologies. The broader biotech sector continues to benefit from a 7-year compound annual growth rate (CAGR) of ~ 12 % in antibody therapeutics, while FDA’s accelerated approval pathways keep timelines compressed for high-need indications.

For a deeper quantitative view of Xencor’s valuation metrics and peer comparison, you may find ValueRay’s analyst toolkit useful.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-138.7m TTM) > 0 and > 6% of Revenue (6% = 10.0m TTM)
FCFTA -0.17 (>2.0%) and ΔFCFTA -2.48pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 258.1% (prev 473.2%; Δ -215.1pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.16 (>3.0%) and CFO -139.0m <= Net Income -138.7m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 5.99 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (74.4m) change vs 12m ago 16.23% (target <= -2.0% for YES)
Gross Margin 64.74% (prev 87.87%; Δ -23.12pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 18.07% (prev 10.34%; Δ 7.73pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -1.36 (EBITDA TTM -68.6m / Interest Expense TTM 58.5m) >= 6 (WARN >= 3)

Altman Z'' -3.67

(A) 0.50 = (Total Current Assets 518.4m - Total Current Liabilities 86.5m) / Total Assets 868.8m
(B) -0.91 = Retained Earnings (Balance) -789.3m / Total Assets 868.8m
(C) -0.09 = EBIT TTM -79.5m / Avg Total Assets 926.2m
(D) -3.23 = Book Value of Equity -787.4m / Total Liabilities 243.5m
Total Rating: -3.67 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 12.57

1. Piotroski 0.0pt
2. FCF Yield -17.56%
3. FCF Margin -85.85%
4. Debt/Equity 0.32
5. Debt/Ebitda -2.54
6. ROIC - WACC (= -21.91)%
7. RoE -21.65%
8. Rev. Trend -34.31%
9. EPS Trend -46.13%

What is the price of XNCR shares?

As of December 30, 2025, the stock is trading at USD 15.17 with a total of 438,904 shares traded.
Over the past week, the price has changed by -5.01%, over one month by -8.12%, over three months by +31.34% and over the past year by -36.02%.

Is XNCR a buy, sell or hold?

Xencor has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy XNCR.
  • Strong Buy: 8
  • Buy: 3
  • Hold: 0
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the XNCR price?

Issuer Target Up/Down from current
Wallstreet Target Price 28.3 86.2%
Analysts Target Price 28.3 86.2%
ValueRay Target Price 14.7 -3%

XNCR Fundamental Data Overview December 28, 2025

Market Cap USD = 1.09b (1.09b USD * 1.0 USD.USD)
P/S = 7.2394
P/B = 1.7644
Beta = 0.964
Revenue TTM = 167.4m USD
EBIT TTM = -79.5m USD
EBITDA TTM = -68.6m USD
Long Term Debt = 115.2m USD (from longTermDebt, last fiscal year)
Short Term Debt = 49.3m USD (from shortTermDebt, last quarter)
Debt = 202.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 174.1m USD (from netDebt column, last quarter)
Enterprise Value = 818.2m USD (1.09b + Debt 202.4m - CCE 471.0m)
Interest Coverage Ratio = -1.36 (Ebit TTM -79.5m / Interest Expense TTM 58.5m)
FCF Yield = -17.56% (FCF TTM -143.7m / Enterprise Value 818.2m)
FCF Margin = -85.85% (FCF TTM -143.7m / Revenue TTM 167.4m)
Net Margin = -82.91% (Net Income TTM -138.7m / Revenue TTM 167.4m)
Gross Margin = 64.74% ((Revenue TTM 167.4m - Cost of Revenue TTM 59.0m) / Revenue TTM)
Gross Margin QoQ = 87.62% (prev 93.92%)
Tobins Q-Ratio = 0.94 (Enterprise Value 818.2m / Total Assets 868.8m)
Interest Expense / Debt = 3.79% (Interest Expense 7.67m / Debt 202.4m)
Taxrate = -0.0% (0.0 / -6.03m)
NOPAT = -79.5m (EBIT -79.5m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 5.99 (Total Current Assets 518.4m / Total Current Liabilities 86.5m)
Debt / Equity = 0.32 (Debt 202.4m / totalStockholderEquity, last quarter 625.3m)
Debt / EBITDA = -2.54 (negative EBITDA) (Net Debt 174.1m / EBITDA -68.6m)
Debt / FCF = -1.21 (negative FCF - burning cash) (Net Debt 174.1m / FCF TTM -143.7m)
Total Stockholder Equity = 640.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -15.97% (Net Income -138.7m / Total Assets 868.8m)
RoE = -21.65% (Net Income TTM -138.7m / Total Stockholder Equity 640.8m)
RoCE = -10.52% (EBIT -79.5m / Capital Employed (Equity 640.8m + L.T.Debt 115.2m))
RoIC = -11.66% (negative operating profit) (NOPAT -79.5m / Invested Capital 681.7m)
WACC = 10.25% (E(1.09b)/V(1.29b) * Re(11.45%) + D(202.4m)/V(1.29b) * Rd(3.79%) * (1-Tc(-0.0)))
Discount Rate = 11.45% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.59%
Fair Price DCF = unknown (Cash Flow -143.7m)
EPS Correlation: -46.13 | EPS CAGR: -18.84% | SUE: 2.31 | # QB: 2
Revenue Correlation: -34.31 | Revenue CAGR: -41.22% | SUE: -0.33 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.64 | Chg30d=-0.013 | Revisions Net=-1 | Analysts=8
EPS next Year (2026-12-31): EPS=-2.67 | Chg30d=-0.006 | Revisions Net=+0 | Growth EPS=-46.1% | Growth Revenue=-6.8%

Additional Sources for XNCR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle